RxDoctor Payments DataLook up a doctor →

Elizabeth Bertschy, NP

Nurse Practitioner · Lees Summit, MONPI 1114465457

Payments from drug & device makers

$15,185in general payments, 2019–2025

Across 789 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$2K
  • QOL Medical, LLC$738
  • Lilly USA, LLC$709
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$14,99799%
  • Education$1871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,185 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$25,041
Medicare patients
186
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$88,828
CreonLipase/Protease/Amylase21$45,647
LinzessLinaclotide28$27,018
IbsrelaTenapanor Hcl11$19,637
Mesalamine18$4,693
Lubiprostone30$3,658
Dexlansoprazole DrDexlansoprazole13$2,475
Sucralfate36$1,829
Pantoprazole Sodium143$1,607
Omeprazole64$913
Midodrine Hcl11$896
ConstuloseLactulose17$694
Spironolactone20$498
Dicyclomine Hcl15$436
Tamsulosin Hcl12$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,305$88,82829 claims
AbbVieCreon, Linzess$3,337$72,66549 claims
Ardelyx, Inc.Ibsrela$587$19,63711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →